1174 related articles for article (PubMed ID: 8865537)
1. Non neutralizing antibodies to tissue type plasminogen activator in the serum of acute myocardial infarction patients treated with the recombinant protein.
Cugno M; Cicardi M; Colucci M; Bisiani G; Merlini PA; Spinola A; Paonessa R; Agostoni A
Thromb Haemost; 1996 Aug; 76(2):234-8. PubMed ID: 8865537
[TBL] [Abstract][Full Text] [Related]
2. Anti-t-PA antibodies in acute myocardial infarction after thrombolysis with rt-PA.
Cugno M; Castelli R; Bisiani G; Griffini S; Meroni PL
Eur J Intern Med; 2010 Feb; 21(1):25-9. PubMed ID: 20122609
[TBL] [Abstract][Full Text] [Related]
3. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
4. [New thrombolytic agents in myocardial infarction].
Charbonnier B; Lang M; Brochier M
Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
[TBL] [Abstract][Full Text] [Related]
5. [Platelet activation in the early phases of acute myocardial infarction].
Salvioni A; Giraldi F; Assanelli E; Lauri G; Grazi M; Pardea S; Marenzi G
Cardiologia; 1998 Aug; 43(8):825-32. PubMed ID: 9808873
[TBL] [Abstract][Full Text] [Related]
6. Clopidogrel-rt-PA-heparin combination in the treatment of acute myocardial infarction.
Bassand JP; Cariou R; Grollier G; Kragten J; Wolf JE; Heyndrickx GR
Semin Thromb Hemost; 1999; 25 Suppl 2():69-75. PubMed ID: 10440428
[TBL] [Abstract][Full Text] [Related]
7. [Tissue plasminogen activator (t-PA) in myocardial infarction. Biological aspects].
Samama M; Verdy E; Conard J; Vahanian A; Michel P; Van Dreden P; Nguyen G; Horellou MH; Combrisson A; Acar J
Arch Mal Coeur Vaiss; 1986 Oct; 79(11):1618-24. PubMed ID: 3103572
[TBL] [Abstract][Full Text] [Related]
8. Low incidence of antibodies to recombinant human tissue-type plasminogen activator in treated patients.
Reed BR; Chen AB; Tanswell P; Prince WS; Wert RM; Glaesle-Schwarz L; Grossbard EB
Thromb Haemost; 1990 Oct; 64(2):276-80. PubMed ID: 2125377
[TBL] [Abstract][Full Text] [Related]
9. Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction.
van Griensven JM; Koster RW; Burggraaf J; Huisman LG; Kluft C; Kroon R; Schoemaker RC; Cohen AF
Clin Pharmacol Ther; 1998 Jan; 63(1):39-47. PubMed ID: 9465840
[TBL] [Abstract][Full Text] [Related]
10. Influence of cardiac output on peak t-PA plasma levels in patients receiving thrombolytic therapy with recombinant tissue-type plasminogen activator--correlation with patency rate.
Huber K; Beckmann R; Probst P; Rauscha F; Kaindl F; Binder BR
Thromb Haemost; 1993 Jan; 69(1):45-9. PubMed ID: 8446938
[TBL] [Abstract][Full Text] [Related]
11. Relationship of plasminogen activator inhibitor-1 levels following thrombolytic therapy with rt-PA as compared to streptokinase and patency of infarct related coronary artery.
Paganelli F; Alessi MC; Morange P; Maixent JM; Lévy S; Vague IJ
Thromb Haemost; 1999 Jul; 82(1):104-8. PubMed ID: 10456462
[TBL] [Abstract][Full Text] [Related]
12. [Anaphylactoid reaction during administration of tissue plasminogen activator (t-PA)].
Cannas S; De Leo A; Marzari A
G Ital Cardiol; 1997 Mar; 27(3):278-80. PubMed ID: 9244730
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of tissue plasminogen activator and plasminogen activator inhibitor-I levels in acute myocardial infarction.
Yamada S; Yamada R; Ishii A; Ashikawa K; Kawamitsu H; Fujita K
J Cardiol; 1996 Apr; 27(4):171-8. PubMed ID: 8642503
[TBL] [Abstract][Full Text] [Related]
14. Procoagulant properties of intravenous staphylokinase versus tissue-type plasminogen activator.
Okada K; Lijnen HR; Moreau H; Vanderschueren S; Collen D
Thromb Haemost; 1996 Dec; 76(6):857-9. PubMed ID: 8972000
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies.
Wojta J; Turcu L; Wagner OF; Korninger C; Binder BR
J Lab Clin Med; 1987 Jun; 109(6):665-71. PubMed ID: 3108431
[TBL] [Abstract][Full Text] [Related]
16. [Intravenous infusion of recombinant tissue-type plasminogen activator (rt-PA) and urokinase in acute myocardial infarct: intermediate results of the G.A.U.S. study (German Activator Urokinase Study)].
Neuhaus KL; Tebbe U; Gottwik M; Weber MA; Feuerer W; Niederer W; Haerer W; Praetorius F; Grosser KD; Huhmann W
Klin Wochenschr; 1988; 66 Suppl 12():102-8. PubMed ID: 3126339
[TBL] [Abstract][Full Text] [Related]
17. The role of type-1 plasminogen activator inhibitor in failure of thrombolytic therapy with recombinant tissue plasminogen activator.
Huber K; Beckmann R; Rauscha F; Probst P; Kaindl F; Binder BR
Z Kardiol; 1993; 82 Suppl 2():195-200. PubMed ID: 8328203
[TBL] [Abstract][Full Text] [Related]
18. Treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator.
Glazier JJ; Crowley J; Cremin D; Coll T; Daly K
Ir Med J; 1989 Sep; 82(3):111-4. PubMed ID: 2513287
[TBL] [Abstract][Full Text] [Related]
19. Hepatocyte growth factor plasma levels after myocardial infarction are not affected by recombinant tissue-type plasminogen-activator therapy.
Molnar C; Buratti T; Wiedermann CJ; Tilg H
Eur Cytokine Netw; 2000 Mar; 11(1):87-90. PubMed ID: 10705304
[TBL] [Abstract][Full Text] [Related]
20. [The absence of a procoagulant effect after TNK-t-PA: a comparison with streptokinase and rt-PA].
De Marco E; Andreotti F; van de Greef W; Quaranta G; Biasucci LM; Kol A; Maseri A; Rebuzzi AG
Cardiologia; 1998 Nov; 43(11):1209-13. PubMed ID: 9922587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
